{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:57:47Z","timestamp":1794333467433,"version":"4.9.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1097\/01.jcp.0000104908.75206.26","type":"journal-article","created":{"date-parts":[[2004,9,2]],"date-time":"2004-09-02T03:51:48Z","timestamp":1094097108000},"page":"4-10","source":"Crossref","is-referenced-by-count":40,"title":["Comparative CYP3A4 Inhibitory Effects of Venlafaxine, Fluoxetine, Sertraline, and Nefazodone in Healthy Volunteers"],"prefix":"10.1097","volume":"24","author":[{"given":"C. Lindsay","family":"DeVane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi L.","family":"Liston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth T.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Craig","family":"Risch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Willard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 1","key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/(SICI)1520-6394(1998)8:1+<64::AID-DA10>3.0.CO;2-S","article-title":"Translational pharmacokinetics: focus on newer antidepressants.","volume":"8","author":"DeVane","year":"1998","journal-title":"Anxiety Depress"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1023\/A:1006934807375","article-title":"Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.","volume":"19","author":"DeVane","year":"1999","journal-title":"Cell Mol Neurobiol"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1176\/ajp.153.3.311","article-title":"Newer antidepressants and the cytochrome P450 system.","volume":"153","author":"Nemeroff","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2125.1997.00591.x","article-title":"Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.","volume":"43","author":"Ball","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00004714-199512000-00002","article-title":"The emerging role of cytochrome P450 3A in psychopharmacology.","volume":"15","author":"Ketter","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism.","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit Rev Toxicol"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0006-3223(96)00406-4","article-title":"Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms.","volume":"41","author":"von Moltke","year":"1997","journal-title":"Biol Psychiatry"},{"key":"R9-2-20210128","first-page":"211","article-title":"Effect of venlafaxine on the pharmacokinetics of alprazolam.","volume":"34","author":"Amchin","year":"1998","journal-title":"Psychopharmacol Bull"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/j.1552-4604.1996.tb04252.x","article-title":"Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.","volume":"36","author":"Greenblatt","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation.","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/clpt.1991.98","article-title":"Increased carbamazepine plasma concentrations after fluoxetine coadministration.","volume":"50","author":"Grimsley","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0009-9236(97)90084-9","article-title":"Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.","volume":"62","author":"Bergstrom","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF02246031","article-title":"Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.","volume":"104","author":"Lasher","year":"1991","journal-title":"Psychopharmacology"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/clpt.1992.175","article-title":"Fluoxetine impairs clearance of alprazolam but not of clonazepam.","volume":"52","author":"Greenblatt","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1994.tb04317.x","article-title":"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.","volume":"38","author":"von Moltke","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-199706000-00021","article-title":"Awareness of potential drug interactions may aid avoidance.","volume":"19","author":"DeVane","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R18-2-20210128","first-page":"43","article-title":"Possible interaction of sertraline with carbamazepine.","volume":"107","author":"Joblin","year":"1994","journal-title":"NZ Med J"},{"key":"R19-2-20210128","first-page":"20","article-title":"Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine.","volume":"57","author":"Rapeport","year":"1996","journal-title":"J Clin Psychol"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00004714-200010000-00020","article-title":"Lack of effect of sertraline on the pharmacokinetics of alprazolam.","volume":"20","author":"Preskorn","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00004714-200004000-00006","article-title":"Dose-response evaluation of the interaction between sertraline and alprazolam in vivo.","volume":"20","author":"Hassan","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00004714-199512000-00004","article-title":"Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam.","volume":"15","author":"Greene","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s002130051039","article-title":"Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.","volume":"145","author":"von Moltke","year":"1999","journal-title":"Psychopharmacology"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-4347(97)00225-9","article-title":"Modified high-performance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping.","volume":"696","author":"Hoskins","year":"1997","journal-title":"J Chromatogr B"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1023\/A:1006934807375","article-title":"Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.","volume":"19","author":"DeVane","year":"1999","journal-title":"Cell Mol Neurobiol"},{"issue":"suppl","key":"R26-2-20210128","first-page":"10","article-title":"Pharmacology of antidepressants: focus on nefazodone.","volume":"63","author":"DeVane","year":"2002","journal-title":"J Clin Psychol"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1992.18","article-title":"Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction.","volume":"51","author":"Bergstrom","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-199408000-00001","article-title":"Noninvasive tests of CYP3A enzymes.","volume":"4","author":"Watkins","year":"1994","journal-title":"Pharmacogenetics"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0378-4347(00)83150-3","article-title":"Alprazolam, alpha-hydroxy and 4-hydroxyalprazolam analysis in plasma by high performance liquid chromatography.","volume":"430","author":"Miller","year":"1988","journal-title":"J Chromatogr B"},{"key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1177\/009127009703700121","article-title":"Use of probe drugs as predictors of drug metabolism in humans.","volume":"37","author":"Kivisto","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"R31-2-20210128","first-page":"62","article-title":"A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.","volume":"35","author":"Levin","year":"2001","journal-title":"Psychopharm Bull"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00004714-199512000-00003","article-title":"Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.","volume":"15","author":"Greene","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/clpt.1993.199","article-title":"Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.","volume":"54","author":"Kinirons","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R34-2-20210128","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0009-9236(99)70029-9","article-title":"Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.","volume":"66","author":"Kinirons","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1067\/mcp.2002.128387","article-title":"Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.","volume":"72","author":"Paine","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","article-title":"Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.","volume":"10","author":"Streetman","year":"2000","journal-title":"Pharmacogenetics"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00003088-200140030-00001","article-title":"The erythromycin breath test for the prediction of drug clearance.","volume":"40","author":"Rivory","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI116064","article-title":"Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.","volume":"90","author":"Kolars","year":"1992","journal-title":"J Clin Invest"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/00912700022008702","article-title":"CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.","volume":"40","author":"Alfaro","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2165\/00003088-200241150-00002","article-title":"Clinical pharmacokinetics of sertraline.","volume":"41","author":"DeVane","year":"2002","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.jcp.0000104908.75206.26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:46:22Z","timestamp":1620938782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200402000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000104908.75206.26","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}